Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Result of General Meeting

8th Jul 2024 12:45

RNS Number : 5382V
Belluscura PLC
08 July 2024
 

8 July 2024

 

Belluscura plc

("Belluscura", the "Company"}

 

Result of General Meeting

 

Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that at the General Meeting held earlier today both the resolutions put to the meeting were duly approved by Shareholders:

 

Resolution(*indicates special resolution)

Votes for

% of shares voted

Votes against

% of shares voted

Resolution 1: To allot Shares re. Loan Notes.

98,167,364

99.90%

101,411

0.10%

Resolution 2*: To disapply StatutoryPre-Emption Rights re. Loan Notes.

98,167,364

99.90%

101,411

0.10%

 

The Company is pleased to confirm that, as announced on 2 July 2024, following Shareholder approval for the Resolutions as they relate to the issue of the Loan Note Placing, together with the recent Share Subscriptions for new ordinary shares, the Company has raised total gross proceeds of approximately £1.92 million.

 

In accordance with the terms of the Loan Note Placing Agreement, following passing of the Resolutions, the Placing Loan Notes will be issued on 9 July 2024.

 

The net proceeds of the Loan Note Placing and Share Subscriptions will be used for working capital purposes to support the growth in both the X-PLOR® and DISCOV-RTM portable oxygen concentrator devices sales, as set out in the Announcement and the Letter to Shareholders dated 2 July 2024.

 

 

Capitalised terms used in this announcement shall, unless defined in this announcement or unless the context provides otherwise, bear the same meaning ascribed to such terms in the Announcement made by the Company at 14:30 on 2 July 2024 and the letter to Shareholders dated 2 July 2024, which constituted a supplement to the Circular dated 14 June 2024.

 

For further information please contact:

 

Belluscura plc

Tel: +44 (0)20 3128 8100

Adam Reynolds, Chairman

Robert Rauker, Chief Executive Officer

Simon Neicheril, Chief Financial Officer

SPARK Advisory Partners Limited (Nomad)

Tel: +44 (0)20 3368 3550

Neil Baldwin / Jade Bayat

Dowgate Capital Limited (Broker)

Tel: +44 (0)20 3903 7715

Russell Cook / Nicholas Chambers

MHP (Financial PR & Investor Relations)

Tel: +44 (0)20 3128 8100

Katie Hunt / Matthew Taylor 

 [email protected]

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMEAFXPELELEFA

Related Shares:

Belluscura
FTSE 100 Latest
Value8,871.31
Change61.57